Status:
COMPLETED
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease
Lead Sponsor:
Shire
Conditions:
Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate. The body's attempt to adjust to an increased level of phosphate in the blood can result in elevated levels...
Eligibility Criteria
Inclusion
- Under a physician's care for CKD for \> 2 months and are not expected to begin dialysis for 4 months
- Screening estimated GFR of 15-59 mL/1.73 m2
- Serum phosphorus \>= 4.7 mg/d following washout
Exclusion
- Requiring treatment with cinacalcet HCI or compounds containing phosphate, aluminum, calcium or magnesium
- Rapidly progressing glomerulonephritis
- Cirrhosis or other clinically significant liver diseases
- Past or present uncontrolled peptic ulcer, Crohn's disease, malignancy or recent GI bleed
Key Trial Info
Start Date :
January 11 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT00234702
Start Date
January 11 2006
End Date
June 1 2007
Last Update
June 8 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Greater Los Angeles Health Care System
Los Angeles, California, United States, 90073
2
Barnett Research & Communications Medical Corporation
Torrance, California, United States, 90503
3
Western Nephrology & Metabolic Bone Disease, PC
Thornton, Colorado, United States, 80260
4
Outcomes Research International, Inc.
Hudson, Florida, United States, 34667